CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be hosted April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The first poster presentation will highlight new nonclinical data on the unique properties of bezuclastinib that differentiate it from other KIT inhibitors. Bezuclastinib is currently under clinical investigation in Advanced Systemic Mastocytosis (NCT04996875), Nonadvanced Systemic Mastocytosis (NCT05186753), and imatinib-resistant Gastrointestinal Stromal Tumors (GIST) (NCT05208047). A second poster presentation will reveal in vitro and in vivo characteristics of a novel series of FGFR inhibitors with potency against clinically relevant mutations. Details for the poster presentations are as follows: Abstract Number: 147 Title: Bezuclastinib is a differentiated KIT inhibitor that exhibits unique selectivity to KIT A-loop mutations, minimal brain penetration, and favorable pharmacokinetic properties in preclinical modelsSession Category: Molecular/Cellular Biology and GeneticsSession Title: Kinases and PhosphatasesSession Date and Time: Sunday, April 10, 2022, 1:30 – 5:00PM CTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 8 Abstract Number: 167 Title: Pre-clinical characterization of a novel series of FGFR2 selective inhibitors with potency against clinically relevant mutationsSession Category: Molecular/Cellular Biology and GeneticsSession Title: Kinases and PhosphatasesSession Date and Time: Sunday, April 10, 2022, 1:30 – 5:00PM CTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 8 About Cogent Biosciences, Inc.Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s planned poster presentations at the AACR annual meeting 2022.The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in Cogent’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Media contact:Amanda Sellersasellers@vergescientific.com 301.332.5574